Enoxaparin sodium

Techdow USA Announces Launch of its Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) in Prefilled Syringes

Retrieved on: 
Thursday, June 8, 2023
General Health, Medical Devices, Health, Pharmaceutical, Medical Supplies, Abbreviated New Drug Application, Heparin, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., USP, Sale, Blood, Oligosaccharide, Thrombosis, RLD, Enoxaparin sodium, LMWH, Sanofi, FDA, Syringe, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Generic drug, Fine chemical

Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the launch of its 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a therapeutic equivalent for the reference listed drug (RLD) Lovenox® (Preservative Free) from Sanofi-Aventis US LLC.

Key Points: 
  • Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the launch of its 30mg, 40mg, 60mg, 80mg, 100mg, 120mg, and 150mg strengths of generic Enoxaparin Sodium (Preservative Free) Prefilled Syringes, a therapeutic equivalent for the reference listed drug (RLD) Lovenox® (Preservative Free) from Sanofi-Aventis US LLC.
  • Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $530 million, according to IQVIA Health over a 12-month period ending March 2023.
  • Techdow USA’s Enoxaparin Sodium (Preservative Free) Prefilled Syringes are supplied in 10-pack single-dose for subcutaneous (SQ) use.
  • Techdow USA is among the fastest growing companies in the US generic pharmaceutical industry, specializing in the sale of generic injectable pharmaceuticals.

Techdow USA Announces FDA Approval of Generic Lovenox®, (Enoxaparin Sodium – Preservative Free) In Prefilled Syringes

Retrieved on: 
Monday, March 20, 2023
FDA, Pharmaceutical, Health, Medical Supplies, Akwa Ibom State Association of Nigeria, USA Inc., Sale, Sanofi, Environment, Syringe, Pharmaceutical industry, Fine chemical, Enoxaparin sodium

Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.

Key Points: 
  • Techdow USA Inc. (“Techdow USA”), a growing market leader and vertically integrated generic injectables company, today announced the FDA approval of Enoxaparin Sodium (Preservative Free) in Prefilled Syringes for the U.S. market.
  • “Techdow USA is excited to bring this critical product to institutions, retail and other networks in need of a safe, affordable and reliable source of Enoxaparin,” said Darren Alkins, Chief Executive Officer of Techdow USA.
  • Enoxaparin Sodium (Preservative Free) Prefilled Syringes had US brand and generic sales of approximately $550 million, according to IQVIA Health for the 12 months ending December, 2022.
  • To report SUSPECTED ADVERSE REACTIONS, contact Hepalink USA, Inc./Techdow USA, Inc. at 1-888-355-1375 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

Low Molecular Weight Heparin Market Forecast to 2028 - Global Analysis by Enoxaparin, Dalteparin, Tinzaparin, Fraxiparine, Nadroparin - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 2, 2022
Pharmaceutical, Health, Other Health, Myocardial infarction, Risk, LMWH, ACS, Patient, Anticoagulant, Hospital, Thrombosis, Heparin, Enoxaparin sodium, Plasma, Calcium hypochlorite, COVID-19, Nadroparin calcium, Syringe, Deep vein thrombosis, Geography, CAGR, Atomic mass, Dalteparin sodium, Pulmonary embolism, Half-life, Osteoporosis, UFH, HIT, Acute coronary syndrome, Pharmaceutical industry, Sodium, Application, Tinzaparin sodium

The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.

Key Points: 
  • The low molecular weight fractions of heparin have the molecular weight of ~3,500-8,000 Daltons, while unfractionated heparin has a molecular weight of 15,000 Daltons; thus, the former react less with platelets than the latter.
  • The global low molecular weight heparin market, based on product type, is segmented into enoxaparin, dalteparin, tinzaparin, fraxiparine, nadroparin, and others.
  • The global low molecular weight heparin market, based on packaging, is bifurcated into multi-vials and prefilled syringes.
  • The global low molecular weight heparin market, based on end user, has been segmented into hospitals, clinics, ambulatory surgical centers, and others.

Sandoz Canada launches its 6th biosimilar with Inclunox® and Inclunox® HP (Enoxaparin sodium solution for injection 100 mg/mL and 150 mg/mL (High Potency))

Retrieved on: 
Monday, May 17, 2021
Life sciences, Biotechnology, Health sciences, Biosimilar, Drugs, Pharmaceutical industry, Biopharmaceutical, Enoxaparin sodium

It is one of the first companies to make available a biosimilar version of enoxaparin sodium solution for injection, thus contributing to potentially help lower healthcare costs for Canadian hospitals and private and public payers.

Key Points: 
  • It is one of the first companies to make available a biosimilar version of enoxaparin sodium solution for injection, thus contributing to potentially help lower healthcare costs for Canadian hospitals and private and public payers.
  • The enoxaparin biosimilar market represents more than 6 million syringes administered to patients every year across Canada\xe2\x80\x9d6 declared Michel Robidoux, President and General Manager of Sandoz Canada.
  • These forward-looking statements reflect management\xe2\x80\x99s current beliefs and expectations regarding future events and involve known and unknown risks and significant uncertainties.
  • https://www.canada.ca/en/health-canada/services/drugs-health-products/bi...\nPotential savings associated with biosimilars in Canada: Government of Canada.

Apotex Corp. Issues Voluntary Nationwide Recall of Enoxaparin Sodium Injection, USP Due to Mislabeling of Syringe Barrel Measurement Markings

Retrieved on: 
Tuesday, February 2, 2021
Marketing, Pharmaceutical companies, Companies, Heparins, Apotex, Enoxaparin sodium, FedEx, Notification, Unique selling proposition

The two (2) affected batches of Enoxaparin Sodium Injection, USP were distributed by Apotex nationwide in the USA to Wholesalers and Warehousing Chains.

Key Points: 
  • The two (2) affected batches of Enoxaparin Sodium Injection, USP were distributed by Apotex nationwide in the USA to Wholesalers and Warehousing Chains.
  • Apotex Corp. is currently notifying its affected direct account Wholesalers and Warehousing Chains, via mail (FedEx Standard Overnight) by mailing a recall notification letter and is arranging for return of all recalled product.
  • Patients who have received either of the two (2) impacted batches of Enoxaparin Sodium Injection, USP or have questions regarding this recall should contact their pharmacy.
  • Consumers with questions regarding this recall can contact Apotex Corp. by phone at 1-800-706-5575 (8:30am 5:00pm, EST Monday thru Friday) or email address [email protected] .

Laboratorios Farmacéuticos ROVI (ROVI): All good things come in threes

Retrieved on: 
Friday, December 11, 2020
Heparins, Branches of biology, Biology, Life sciences, TiVo Corporation, Enoxaparin sodium, Vaccine, Low-molecular-weight heparin, Messenger RNA, HIBOR, Rovi, X

Laboratorios Farmacuticos ROVI's (ROVI's) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises.

Key Points: 
  • Laboratorios Farmacuticos ROVI's (ROVI's) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises.
  • Combined unit sales of Becat and Hibor have now overtaken incumbent Clexane sales, establishing ROVI as a leader in low molecular weight heparins (LMWHs).
  • ROVI has signed a deal to provide finished mRNA-1273 vaccine for supply ex US; this is a strong validation of its prefilled syringe fill and finish capabilities.
  • About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac.

Hepalink Announces Exciting Regulatory Developments

Retrieved on: 
Monday, June 29, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Health, Pharmaceutical sciences, Pharmaceutical industry, Pharmacology, Pharmacy, Enoxaparin sodium, Contract manufacturing organization

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399, HKEx: 9989), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced exciting regulatory milestones in both the marketed pharmaceutical business and its pipeline development.

Key Points: 
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE: 002399, HKEx: 9989), a China-based global pharmaceutical company targeting high-mortality diseases with significant unmet medical needs, announced exciting regulatory milestones in both the marketed pharmaceutical business and its pipeline development.
  • On the marketed product front, Hepalinks Inhixa brand enoxaparin sodium injection has obtained the approval for marketing in Switzerland.
  • Hepalink has the Greater China rights of RVX-208.
  • Founded by a group of seasoned polysaccharide-chemists with scientific insights and profound understanding of immunology, Hepalink is a leading China-based pharmaceutical company with global businesses in pharmaceutical, innovative biotech and CDMO sectors.

Meitheal Pharmaceuticals Announces Launch of Enoxaparin Sodium Injection, USP in the United States

Retrieved on: 
Thursday, May 28, 2020
General Health, Pharmaceutical, Health, Enoxaparin sodium, Heparins, RTT, Sanofi, Pharmaceutical industry in China, Pharmaceutical industry in India, Health care, Pharmacy

Meitheal Pharmaceuticals, Inc. (Meitheal) , a fully integrated generic injectables company today announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the United States market.

Key Points: 
  • Meitheal Pharmaceuticals, Inc. (Meitheal) , a fully integrated generic injectables company today announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the United States market.
  • Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder.
  • Enoxaparin had sales of approximately $570,878,217 in the United States, according to IQVIA data as of MAT (Moving Annual Total) March 2020.
  • Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables.

Meitheal Pharmaceuticals Announces FDA Approval of Enoxaparin Sodium Injection, USP in the United States

Retrieved on: 
Thursday, December 5, 2019
Biotechnology, Pharmaceutical, Health, Heparins, Enoxaparin sodium, RTT, Sanofi, Pharmaceutical industry in China, Health care, Pharmacy

Meitheal Pharmaceuticals , Inc. (Meitheal), a fully integrated generic injectables company today announced that the US Food and Drug Administration (FDA) has approved Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox.

Key Points: 
  • Meitheal Pharmaceuticals , Inc. (Meitheal), a fully integrated generic injectables company today announced that the US Food and Drug Administration (FDA) has approved Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox.
  • Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder.
  • Enoxaparin had annual sales of approximately $616M in the United States, according to IQVIA data as of MAT (Moving Annual Total) October 2019.
  • Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables.

Enoxaparin Sodium Market in China 2018: Analysis through 2013 to 2022

Retrieved on: 
Tuesday, July 10, 2018
CAC 40, Sanofi, Enoxaparin sodium, Economy of France, Business, Health

Sanofi's Enoxaparin Sodium Injection was approved by FDA in Oct. 2004, and entered the Chinese market in the beginning of 2005 with a continuous growth in market size.

Key Points: 
  • Sanofi's Enoxaparin Sodium Injection was approved by FDA in Oct. 2004, and entered the Chinese market in the beginning of 2005 with a continuous growth in market size.
  • It is estimated that Sanofi will have ever smaller market share in the coming years with more Enoxaparin Sodium manufacturers entering the market in China.
  • 2 Analysis on Sales of Enoxaparin Sodium in China, 2013-2017
    3 Major Enoxaparin Sodium Manufacturers in China, 2013-2017
    3.3 Hangzhou Jiuyuan Gene Engineering Co., Ltd.
    3.4 Shenzhen Techdow Pharmaceutical Co., Ltd.
    3.5 Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
    3.6 Chengdu Baiyu Pharmaceutical Co., Ltd.
    3.7 Suzhou Erye Pharmaceutical Co., Ltd.
    3.8 Beijing SL Pharmaceutical Co., Ltd.
    3.9 Changzhou Qianhong Bio-pharma Co., Ltd.
    4 Prices of Enoxaparin Sodium in China, 2017-2018
    4.3.2 Hangzhou Jiuyuan Gene Engineering Co., Ltd.
    4.3.3 Shenzhen Techdow Pharmaceutical Co., Ltd.
    4.3.4 Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.
    4.3.5 Chengdu Baiyu Pharmaceutical Co., Ltd.
    4.3.6 Suzhou Erye Pharmaceutical Co., Ltd.
    4.3.7 Beijing SL Pharmaceutical Co., Ltd.
    4.3.8 Changzhou Qianhong Bio-pharma Co., Ltd.
    5 Prospects of Chinese Enoxaparin Sodium Market, 2018-2022
    Chart Sales Value of Enoxaparin Sodium in China, 2013-2017
    Chart Sales Value of Enoxaparin Sodium by Region in China, 2013-2017
    Chart Price of Sanofi's Enoxaparin Sodium in China, 2017-2018
    Chart Profile of Hangzhou Jiuyuan Gene Engineering Co., Ltd.
  • Chart Sales of Hangzhou Jiuyuan Gene Engineering Co., Ltd.'s Enoxaparin Sodium, 2013-2017
    Chart Price of Hangzhou Jiuyuan Gene Engineering Co., Ltd.'s Enoxaparin Sodium in China, 2017-2018
    Chart Forecast on Size of Chinese Enoxaparin Sodium Market, 2018-2022